Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | CHECKMATE 920: nivolumab plus ipilimumab for renal cell cancer

Hamid Emamekhoo • 2 Jun 2019
ASCO 2019
Bladder Cancer Genitourinary Cancer Ipilimumab Nivolumab

Hamid Emamekhoo, MD, of the University of Wisconsin School of Medicine and Public Health, Madison, WI, discusses the CHECKMATE 920 (NCT02982954) study investigating the safety of nivolumab in combination with ipilimumab in subjects with previously untreated advanced or metastatic renal cell cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Hamid Emamekhoo

3:28
CheckMate 920: nivo plus ipi for advanced RCC with brain metastases
Hamid Emamekhoo • 26 May 2021
2:30
Predicting treatment responses with CTCs in ccRCC
Hamid Emamekhoo • 26 May 2021
3:52
Impact of intact P-Rmass on ICI response in mRCC
Hamid Emamekhoo • 9 Feb 2021

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals